** Shares of biotech co Repligen Corp rise 6.09% to $148 premarket
** Raises FY adjusted profit forecast to be in the range of $1.50 to $1.58 per share from $1.42 to $1.49
** Expects FY total revenue to be in the range of $630 mln to $639 mln from its previous estimate of $620 mln to $635 mln
** Reports Q3 revenue of $155 mln, a 10% increase from a year earlier
** Analysts were expecting revenue of $153.2 mln as per data compiled by LSEG
** "We are encouraged to see strengthening CDMO and equipment sales in the quarter, with each delivering year-over-year and sequential growth"- RGEN
** "Net-net, a solid quarter from RGEN and positive forward commentary"- brokerage Stephens
** Up to last close, stock down 22.4% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.